One-year Follow-up of the Hospitalized Schizophrenic Patients Treated with Risperidone or Olanzapine: Aspects in Cost Economy.
- Author:
Chul Eung KIM
1
;
Jin Mi KIM
;
Hey Won MOON
;
Jae Nam BAE
;
Min Hee KANG
Author Information
1. Department of Psychiatry, College of Medicine, Inha University, Inchon, Korea.
- Publication Type:Original Article
- Keywords:
Cost-effectiveness;
Direct medical cost;
Risperidone;
Olanzapine
- MeSH:
Antipsychotic Agents;
Follow-Up Studies*;
Humans;
Risperidone*;
Schizophrenia
- From:Journal of Korean Neuropsychiatric Association
2002;41(6):1081-1088
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: This study was conducted to access the cost-effectiveness of risperidone or olanzapine in a subset of patients with schizophrenia. METHODS: Two schizophrenia patient groups who were with risperidone(n=17) or olanzapine(n=20) were compared with each other in total medical cost, average daily cost of antipsychotics, discharge rate, drop-out rate, readmission rate and extropyramidal side effect(EPS). RESULTS: The average daily costs of risperidone and olanzapine treated groups were \9,778 and \9,536 in admission, and \2,219 and \5,118 in patients one year after discharge respectively. Risperidone group showed higher rate of EPS than olanzapine group. There was no significant difference in discharge or drop-out rate. CONCLUSIONS: Olanzapine group had higher total daily medical cost and daily medication cost, while risperidone group showed higher readmission and EPS rate.
